|
EP3789768A1
|
|
Method for determining the effectiveness of a nanoparticle-based therapy
|
|
EP3771468A1
|
|
C3/c5 convertase assays
|
|
EP3682931A1
|
|
Thoracic catheter
|
|
WO2019068861A1
|
|
Drinking teat and drinking system
|
|
DE102018123360A1
|
|
DEVICE AND METHOD FOR THE PATIENT-INDIVIDUAL COMPILATION OF SOLID, ORAL-TAKABLE MEDICINAL UNITS
|
|
WO2019052610A1
|
|
Implantable valve prosthesis
|
|
WO2019002518A2
|
|
Activators of factor xii binding to the proline rich domain
|
|
WO2020001733A1
|
|
A holding device for microscopy applications and microscopy chamber
|
|
EP3564263A1
|
|
Fusion proteins comprising a cell surface marker specific vhh
|
|
EP3606537A1
|
|
Microrna 19a/19b for use in treating a pathological condition associated with bone loss or reduced muscle function
|
|
US2019350178A1
|
|
Animal model for drug development
|
|
EP3545307A1
|
|
Method for diagnosing different forms of malaria
|
|
WO2019015765A1
|
|
Apparatus for measuring or training an emotion or behavior
|
|
EP3428184A1
|
|
Means for treating cardiovascular disease
|
|
EP3425403A1
|
|
Metabolite marker combinations for prediction of coronary heart disease
|
|
US2019064181A1
|
|
Il-22bp as biomarker in anti-tnf-alpha-treatments
|
|
EP3351094A1
|
|
Animal model for drug development
|
|
EP3351263A1
|
|
Pharmaceutical preparation for treating or preventing tissue adhesion
|
|
EP3332637A1
|
|
Vhh-containing heavy chain antibody and production thereof
|
